Clinical trials: Hepatic Tumor Resection
HCC - Hepatocellular Carcinoma
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
Tumor recurrence is the leading cause of death and a major bottleneck for long-term survival in patients with hepatocellular carcinoma (HCC).
- Trial name
- Ad-rHCC (NCT07658105)
- Testing
- eparlitozoviril, Control group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Resected Liver Metastases From Colorectal Cancer
Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer
This adaptive seamless Phase II/III trial is to compare the efficacy and safety of adjuvant systemic chemotherapy (SCT) with or without hepatic arterial infusion (HAI) after complete hepatic resection for Chinese patients with…
- Trial name
- NCT02529774
- Testing
- Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6), Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Ye Xu
Liver Resection, Liver Tumours
Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA).
Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA) Introduction The mode of parenchymal transection in hepatic resection has been a topic of great debate for decades.
- Conditions
- Liver Resection, Liver Tumours, Liver Transplant Disorder, Trauma Abdomen
- Trial name
- NCT07142876
- Testing
- Liver resection Cavitron Ultrasonic Surgical Aspirator (CUSA), Liver resection with the harmonic scalpel
- Volunteers
- 50 people
- Sponsor
- Sohag University
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
This is a Phase I study, which means we want to find out what effects, good and/or bad, this combination of drugs may have on the patient and the liver cancer at different dose levels.
- Conditions
- Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
- Trial name
- NCT01938729
- Testing
- Liver resection and placement of hepatic artery infusion pump, FLOXURIDINE, DEXAMETHASONE
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma (HCC)
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Primary liver cancer-particularly hepatocellular carcinoma (HCC)-remains a major health burden in China, characterized by high incidence and mortality rates and poor 5-year survival.
- Trial name
- NCT07331883
- Testing
- Sintilimab plus bevacizumab biosimilar
- Where
- 4 sites in China
- Volunteers
- 35 people
- Sponsor
- Ruijin Hospital
Metastatic Colorectal Cancer
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
The purpose of this study is to see if Panitumumab plus the other treatments will increase the time of remission. Remission means that there is no sign of the cancer.
- Trial name
- NCT01312857
- Testing
- panitumumab, Randomization to No Panitumumab
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer
Study hypothesis: The recurrence rate of HCC patients after radical resection is about 60-70%. This study is based on the hypothesis that CIK treatment could decrease the recurrence rate by 15% to 20%.
- Trial name
- HCC-CIK (NCT00769106)
- Testing
- cytokine-induced killer cell (CIK) treatment
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Hepatic Neoplasms
Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method
Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers.
- Trial name
- NCT02213692
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hui-Chuan Sun
Resectable Pancreatic Cancer
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases.
- Trial name
- ICAPAC (NCT03435536)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Toulouse
Liver Neoplasms
Short Term Surgical Outcomes of Anatomical Versus Non Anatomical Laparoscopic Liver Resection for Liver Tumors
aimed to discuss the short term surgical outcomes of Anatomical versus Non anatomical laparoscopic Liver resection for Liver tumors.
- Trial name
- NCT06271109
- Testing
- Anatomical laparoscopic liver resection for liver neoplasms, Non-Anatomical laparoscopic liver resection for liver neoplasms
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Hepatocellular Carcinoma, Malignant Neoplasm
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection.
- Trial name
- NCT03575806
- Testing
- TACE plus autologous Tcm immunotherapy, TACE
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma, RFS
Postoperative Adjuvant Therapy of HCC Based on PD-1
For the treatment of hepatocellular carcinoma, liver resection is still one of the optimal options, but the recurrence rate is as high as 70% five years after the operation, and the prognosis of patients with high-risk recurrence…
- Trial name
- NCT05307926
- Testing
- PD-1 inhibitors, TACE
- Where
- China
- Volunteers
- 573 people
- Sponsor
- Chen Xiaoping
Liver Cancer, Liver Failure
Quantitative MRI and Outcomes of Liver Resection
The present observational study aims to assess the benefit of this quantitative multiparametric magnetic resonance imaging (MRI) in clinical practice, to quantify future liver remnant performance, and to accurately predict the…
- Conditions
- Liver Cancer, Liver Failure, Bile Leak, Liver Metastases
- Trial name
- NCT06181318
- Testing
- Multiparametric MRI scan of the liver
- Volunteers
- 33 people
- Sponsor
- University Hospital Heidelberg
Liver Cancer
The Impact of Fast-track Perioperative Program After Liver Resection in Hong Kong Chinese Patients
Liver cancer was the third leading cause of cancer death in both sexes in Hong Kong and liver resection remains the mainstay of curative treatment.
- Trial name
- NCT03223818
- Testing
- Fast-track peri-operative program
- Where
- Hong Kong
- Volunteers
- 94 people
- Sponsor
- Chinese University of Hong Kong
Colorectal Cancer
Resorbable Barrier for the Prevention of Abdominal and Peri-hepatic Adhesion Formation
The purpose of this study is to evaluate the efficiency of a resorbable barrier membrane for the prevention of abdominal and peri-hepatic adhesion in patients with colorectal cancer requiring two-stage surgery for the resection…
- Trial name
- SEPRAC2T (NCT01262417)
- Testing
- - use of resorbable membrane Seprafilm, without resorbable barrier (seprafilm)
- Where
- 17 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Leon Berard
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.
The project aims to collect blood, tissue samples, and clinical data from patients with primary liver cancer (mainly hepatocellular carcinoma and intrahepatic cholangiocarcinoma) undergoing systemic therapy, surgical resection…
- Trial name
- NCT06899854
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Hepatocellular Carcinoma (HCC), Metastasis
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
This study will evaluate whether resection of the primary liver tumor, in addition to standard first-line systemic therapy, improves survival in patients with hepatocellular carcinoma that has spread outside the liver but still…
- Trial name
- NCT07537959
- Testing
- Primary Tumor Resection, Protocol-Allowed First-Line Immune-Based Systemic Therapy
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Tongji Hospital